Pasar al contenido principal

INMUNOTERAPIA PERSONALIZADA EN MIELOMA MULTIPLE A TRAVES DEL USO DE MODELOS EXPERIMENTALES EN RATON

PI19/00818

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA (IdISNA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

  • Larrayoz, Marta
  • García-Barcina, María
  • Celay, Jon
  • Etxebeste, Amaia
  • Jimenez, Maddalen
  • Perez, Cristina
  • Ordoñez, Raquel
  • Cobaleda, Cesar
  • Botta, Cirino
  • Fresquet, Vicente
  • Roa, Sergio
  • Goicoechea, Ibai
  • Maia, Catarina
  • Lasaga, Miren
  • Chesi, Marta
  • Bergsagel, P Leif
  • Larrayoz, Maria J
  • Calasanz, Maria J
  • Campos-Sanchez, Elena
  • Martinez-Cano, Jorge
  • Panizo, Carlos
  • Rodriguez-Otero, Paula
  • Vicent, Silvestre
  • Roncador, Giovanna
  • Gonzalez, Patricia
  • Takahashi, Satoru
  • Katz, Samuel G
  • Walensky, Loren D
  • Ruppert, Shannon M
  • Lasater, Elisabeth A
  • Amann, Maria
  • Lozano, Teresa
  • Llopiz, Diana
  • Sarobe, Pablo
  • Lasarte, Juan J
  • Planell, Nuria
  • Gomez-Cabrero, David
  • Kudryashova, Olga
  • Kurilovich, Anna
  • Revuelta, Maria V
  • Cerchietti, Leandro
  • Agirre, Xabier
  • San Miguel, Jesus
  • Paiva, Bruno
  • Prosper, Felipe
  • Martinez-Climent, Jose A
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK–MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8 T cells with reduced immunosuppressive regulatory T (T) cells, while late MYC acquisition in slow progressors was associated with lower CD8 T cell infiltration and more abundant T cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8 T cells versus T cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8 T/T cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therap, This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (NAV4 and NAV15 projects). Additional support was obtained from Spanish Ministry of Health - Instituto de Salud Carlos III (FIS), grants PI19/00818, PI20/00048, PI20/00260, CIBERONC no. CB16/12/00489 and no. CB16/12/00369, with support from FEDER (Fondo Europeo de Desarrollo Regional); Paula and Rodger Riney Foundation; Accelerator Award Program from the Spanish Association Against Cancer (AECC), Cancer Research United Kingdom (CRUK), and Associazione Italiana per la Ricerca sul Cancro (AIRC); Spanish Ministry of Education and Science, grants SAF2017-83061-R, PLEC2021-008094, and PID2021-128283OA; Fundacion Arnal Planelles; Fundacion Ramon Areces; Banco de Santander; European Research Council Starting Grant (MYELOMANEXT); CRIS Cancer Foundation (PR_EX_2020-02); AICR grant 24534, 2021; and Leukemia Lymphoma Society. M.C. and P.L.B. were supported by RO1 CA234181. L.C. was supported by R01 CA242069. M.L. was supported by a junior investigator grant from AECC. M.J.G.-B. was supported by Fundacion Arnal Planelles. J.C. was supported by AECC through the ‘Accelerator’ Award. S.R. was supported by RYC-2014-16399/MEC. J.M.C. is the recipient of an FPU fellowship from Universidad Autonoma de Madrid.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

  • Botta, Cirino
  • Perez, Cristina|||0000-0003-3586-2666
  • Larrayoz, Marta|||0000-0001-6097-8244
  • Puig, Noemí|||0000-0001-7535-3861
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Termini, Rosalinda
  • Goicoechea, Ibai|||0000-0002-5329-2225
  • Rodriguez, Sara|||0000-0001-6509-0447
  • Zabaleta, Aintzane|||0000-0003-3474-3040
  • Lopez, Aitziber
  • Sarvide, Sarai
  • Blanco Fernández, Laura|||0000-0002-1859-0884
  • Papetti, Daniele Marco|||0000-0002-3574-6027
  • Nobile, M.S.
  • Besozzi, Daniela
  • Gentile, Massimo
  • Correale, Pierpaolo
  • Siragusa, Sergio
  • Oriol, Albert|||0000-0001-6804-2221
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Sureda, Anna|||0000-0002-1238-6970
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Ríos-Tamayo, Rafael|||0000-0001-8193-1402
  • Moraleda, José María|||0000-0001-9080-1466
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Bargay, Joan|||0000-0002-6739-3916
  • Palomera, Luís
  • Pérez-Montaña, Albert
  • Goldschmidt, Hartmut|||0000-0003-0961-0035
  • Avet-Loiseau, Hervé
  • Roccaro, Aldo|||0000-0002-1872-5128
  • Orfao, Alberto|||0000-0002-0007-7230
  • Martinez-Lopez, Joaquín
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Mateos, M. V.|||0000-0003-2390-1218
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Martinez Climent, Juan-José|||0000-0002-7938-3950
  • Paiva, Bruno|||0000-0003-1977-3815
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed multiple immune checkpoints, suggesting a potentially dysfunctional phenotype. Dual targeting of PD-1 + LAG3 or PD-1 + TIGIT partially restored their function in mice with MM. We identify phenotypic hallmarks of large intratumoral T cell clones, and demonstrate that the CD27 and CD27 T cell ratio, measured by flow cytometry, may serve as a surrogate of clonal T cell expansions and an independent prognostic factor in 543 patients with MM treated with lenalidomide-based treatment combinations.